DK2211892T3 - Sammensætninger omfattende myelinbasiske proteinpeptider og medicinske anvendelser deraf - Google Patents
Sammensætninger omfattende myelinbasiske proteinpeptider og medicinske anvendelser derafInfo
- Publication number
- DK2211892T3 DK2211892T3 DK08844568.9T DK08844568T DK2211892T3 DK 2211892 T3 DK2211892 T3 DK 2211892T3 DK 08844568 T DK08844568 T DK 08844568T DK 2211892 T3 DK2211892 T3 DK 2211892T3
- Authority
- DK
- Denmark
- Prior art keywords
- basic protein
- compositions
- myelin basic
- protein peptides
- medical applications
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 title abstract 2
- 102000047918 Myelin Basic Human genes 0.000 title abstract 2
- 101710107068 Myelin basic protein Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 206010029240 Neuritis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Marine Sciences & Fisheries (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Confectionery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0721430A GB0721430D0 (en) | 2007-10-31 | 2007-10-31 | Composition |
| GB0800962A GB0800962D0 (en) | 2008-01-18 | 2008-01-18 | Conposition |
| PCT/GB2008/003673 WO2009056833A2 (en) | 2007-10-31 | 2008-10-30 | Composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2211892T3 true DK2211892T3 (da) | 2011-10-31 |
Family
ID=40591554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08844568.9T DK2211892T3 (da) | 2007-10-31 | 2008-10-30 | Sammensætninger omfattende myelinbasiske proteinpeptider og medicinske anvendelser deraf |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US8623827B2 (enExample) |
| EP (1) | EP2211892B1 (enExample) |
| JP (1) | JP5361895B2 (enExample) |
| KR (1) | KR101570383B1 (enExample) |
| CN (1) | CN101848725B (enExample) |
| AT (1) | ATE518546T1 (enExample) |
| AU (1) | AU2008320657B2 (enExample) |
| BR (1) | BRPI0818302B1 (enExample) |
| CA (1) | CA2703170C (enExample) |
| CY (1) | CY1112620T1 (enExample) |
| DK (1) | DK2211892T3 (enExample) |
| EA (1) | EA017999B1 (enExample) |
| EC (1) | ECSP10010211A (enExample) |
| HR (1) | HRP20110724T1 (enExample) |
| IL (1) | IL204662A (enExample) |
| MX (1) | MX2010004698A (enExample) |
| MY (1) | MY158800A (enExample) |
| NZ (1) | NZ583924A (enExample) |
| PL (1) | PL2211892T3 (enExample) |
| PT (1) | PT2211892E (enExample) |
| SI (1) | SI2211892T1 (enExample) |
| WO (1) | WO2009056833A2 (enExample) |
| ZA (1) | ZA201001748B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60143234D1 (de) | 2000-08-21 | 2010-11-18 | Apitope Technology Bristol Ltd | Peptid |
| MX2010004698A (es) | 2007-10-31 | 2010-05-13 | Apitope Technology Bristol Ltd | Composicion. |
| AU2009354040A1 (en) | 2009-10-12 | 2012-05-31 | Lifebio Laboratories Llc | Composition for treatment of Multiple Sclerosis |
| GB201300684D0 (en) | 2013-01-15 | 2013-02-27 | Apitope Int Nv | Peptide |
| GB201603582D0 (en) * | 2016-03-01 | 2016-04-13 | Apitope Int Nv | Peptides |
| GB201700095D0 (en) * | 2017-01-04 | 2017-02-22 | Apitope Int Nv | Composition |
| ES2996275T3 (en) * | 2017-01-04 | 2025-02-12 | Worg Pharmaceuticals Zhejiang Co Ltd | Therapeutic method using dose escalation protocol for tolerogenic peptides |
| US20210093695A1 (en) * | 2017-08-14 | 2021-04-01 | Apitope Technology (Bristol) Limited | Method |
| KR20230171998A (ko) | 2021-04-16 | 2023-12-21 | 코어 파마슈티칼스 디벨롭먼트 컴퍼니 인크. | 면역학적 관용의 유지를 추적하는 방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5817629A (en) * | 1991-10-22 | 1998-10-06 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
| DE60143234D1 (de) * | 2000-08-21 | 2010-11-18 | Apitope Technology Bristol Ltd | Peptid |
| US20040096456A1 (en) | 2000-12-01 | 2004-05-20 | Conti-Fine Bianca M | Method to treat hemophilia |
| GB0202399D0 (en) * | 2002-02-01 | 2002-03-20 | Univ Bristol | Peptide |
| MX2010004698A (es) | 2007-10-31 | 2010-05-13 | Apitope Technology Bristol Ltd | Composicion. |
-
2008
- 2008-10-30 MX MX2010004698A patent/MX2010004698A/es active IP Right Grant
- 2008-10-30 WO PCT/GB2008/003673 patent/WO2009056833A2/en not_active Ceased
- 2008-10-30 JP JP2010530555A patent/JP5361895B2/ja active Active
- 2008-10-30 MY MYPI2010001917A patent/MY158800A/en unknown
- 2008-10-30 BR BRPI0818302-3A patent/BRPI0818302B1/pt active IP Right Grant
- 2008-10-30 PT PT08844568T patent/PT2211892E/pt unknown
- 2008-10-30 CN CN2008801138365A patent/CN101848725B/zh active Active
- 2008-10-30 NZ NZ583924A patent/NZ583924A/en unknown
- 2008-10-30 AT AT08844568T patent/ATE518546T1/de active
- 2008-10-30 US US12/740,976 patent/US8623827B2/en active Active
- 2008-10-30 HR HR20110724T patent/HRP20110724T1/hr unknown
- 2008-10-30 AU AU2008320657A patent/AU2008320657B2/en active Active
- 2008-10-30 DK DK08844568.9T patent/DK2211892T3/da active
- 2008-10-30 EP EP08844568A patent/EP2211892B1/en active Active
- 2008-10-30 KR KR1020107005853A patent/KR101570383B1/ko active Active
- 2008-10-30 SI SI200830411T patent/SI2211892T1/sl unknown
- 2008-10-30 PL PL08844568T patent/PL2211892T3/pl unknown
- 2008-10-30 CA CA2703170A patent/CA2703170C/en active Active
- 2008-10-30 EA EA201070541A patent/EA017999B1/ru not_active IP Right Cessation
-
2010
- 2010-03-11 ZA ZA2010/01748A patent/ZA201001748B/en unknown
- 2010-03-22 IL IL204662A patent/IL204662A/en active IP Right Grant
- 2010-05-28 EC EC2010010211A patent/ECSP10010211A/es unknown
-
2011
- 2011-10-25 CY CY20111101006T patent/CY1112620T1/el unknown
-
2013
- 2013-12-06 US US14/099,463 patent/US9381234B2/en active Active
-
2016
- 2016-06-03 US US15/173,018 patent/US9775880B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2211892T3 (da) | Sammensætninger omfattende myelinbasiske proteinpeptider og medicinske anvendelser deraf | |
| CY1118454T1 (el) | Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες | |
| EA201001883A1 (ru) | Мутанты fgf21 и их применение | |
| EA201171220A1 (ru) | Мутанты fgf21 и их применение | |
| EA201270528A1 (ru) | Композиции цитокинов семейства il-17 и их применение | |
| MX337040B (es) | Moleculas de union a 4-1bb. | |
| WO2017191274A3 (en) | Rna encoding a therapeutic protein | |
| TN2009000291A1 (en) | Inhibitors of mek | |
| CY1116435T1 (el) | Ενωσεις βορονικου εστερα και φαρμακευτικες συνθεσεις αυτων | |
| EA201001322A1 (ru) | Вакцины против хламидиоза | |
| CO6351811A2 (es) | La proteina de tuberculosis rv2386c, composiciones y usos de la misma | |
| MA32771B1 (fr) | Mutants fgf21 et leurs utilisations | |
| MX2009009200A (es) | Tratamiento de enfermedades caracterizadas por la inflamacion. | |
| NO20084368L (no) | Stabile emulsjonsformuleringer | |
| MX2009004038A (es) | Gel de diclofenaco. | |
| PH12017501473A1 (en) | Novel proteins specific for pyoverdine and pyochelin | |
| EA201101521A1 (ru) | Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния | |
| EA201070271A1 (ru) | Пептиды для получения вакцины | |
| EA201592264A1 (ru) | Композиции, которые индуцируют хелперное действие т-клеток | |
| MX2015011199A (es) | Agentes terapéuticos de csf1. | |
| EA201000903A1 (ru) | Антитела к pcrv-антигену pseudomonas aeruginosa | |
| CO6400198A2 (es) | Composiciones y metodos novedosos | |
| BR112014010806A2 (pt) | ligadores à base de tirosina para a ligação reversível de peptídeos | |
| CY1115436T1 (el) | Αναστολεις της κινασης p70 s6 | |
| EA200970792A1 (ru) | Аморфный твёрдый раствор, содержащий производное пиразол-3-карбоксамида в аморфной форме и стабилизирующие эксципиенты |